Summary

Brain Ventricular Microinjections of Lipopolysaccharide into Larval Zebrafish to Assess Neuroinflammation and Neurotoxicity

Published: August 23, 2022
doi:

Summary

This protocol demonstrates the microinjection of lipopolysaccharide into the brain ventricular region in a zebrafish larval model to study the resulting neuroinflammatory response and neurotoxicity.

Abstract

Neuroinflammation is a key player in various neurological disorders, including neurodegenerative diseases. Therefore, it is of great interest to research and develop alternative in vivo neuroinflammation models to understand the role of neuroinflammation in neurodegeneration. In this study, a larval zebrafish model of neuroinflammation mediated by ventricular microinjection of lipopolysaccharide (LPS) to induce an immune response and neurotoxicity was developed and validated. The transgenic zebrafish lines elavl3:mCherry, ETvmat2:GFP, and mpo:EGFP were used for real-time quantification of brain neuron viability by fluorescence live imaging integrated with fluorescence intensity analysis. The locomotor behavior of zebrafish larvae was recorded automatically using a video-tracking recorder. The content of nitric oxide (NO), and the mRNA expression levels of inflammatory cytokines including interleukin-6 (IL-6), interleukin-1β (IL-1β), and human tumor necrosis factor α (TNF-α) were investigated to assess the LPS-induced immune response in the larval zebrafish head. At 24 h after the brain ventricular injection of LPS, loss of neurons and locomotion deficiency were observed in zebrafish larvae. In addition, LPS-induced neuroinflammation increased NO release and the mRNA expression of IL-6, IL-1β, and TNF-α in the head of 6 days post fertilization (dpf) zebrafish larvae, and resulted in the recruitment of neutrophils in the zebrafish brain. In this study, injection of zebrafish with LPS at a concentration of 2.5-5 mg/mL at 5 dpf was determined as the optimum condition for this pharmacological neuroinflammation assay. This protocol presents a new, quick, and efficient methodology for brain ventricle microinjection of LPS to induce LPS-mediated neuroinflammation and neurotoxicity in a zebrafish larva, which is useful for studying neuroinflammation and could also be used as a high-throughput in vivo drug screening assay.

Introduction

Neuroinflammation has been described as a crucial anti-neurogenic factor involved in the pathogenesis of several neurodegenerative diseases of the central nervous system (CNS)1. Following pathological insults, neuroinflammation may result in various adverse consequences, including inhibition of neurogenesis and induction of neuronal cell death2,3. In the process underlying the response to inflammation induction, multiple inflammatory cytokines (such as TNF-α, IL-1β, and IL-6) are secreted into the extracellular space and act as crucial components in neuron death and the suppression of neurogenesis4,5,6.

Microinjection of inflammation mediators (such as IL-1β, L-arginine, and endotoxins) into brain can cause neuronal cell reduction and neuroinflammation7,8,9. Lipopolysaccharide (LPS, Figure 1), a pathogenic endotoxin present in the cell wall of Gram-negative bacteria, can induce neuroinflammation, exacerbate neurodegeneration, and reduce neurogenesis in animals10. LPS injection directly into the CNS of the mouse brain increased levels of nitric oxide, pro-inflammatory cytokines, and other regulators11. Furthermore, stereotaxic injection of LPS into the local brain environment can induce excessive production of neurotoxic molecules, resulting in impaired neuronal function and subsequent development of neurodegenerative diseases10,12,13,14,15. In the neuroscience field, live and time-course microscopic observations of cellular and biological processes in living organisms are crucial for understanding the mechanisms underlying pathogenesis and pharmacological action16. However, live imaging of mouse models of neuroinflammation and neurotoxicity is fundamentally constrained by the limited optical penetration depth of microscopy, which precludes functional imaging and live observation of developmental processes17,18,19. Therefore, the development of alternative neuroinflammation models is of great interest to facilitate the study of pathological development, and the mechanism underlying neuroinflammation and neurodegeneration, by live imaging.

Zebrafish (Danio rerio) has emerged as a promising model to study neuroinflammation and neurodegeneration due its evolutionarily conserved innate immune system, optical transparency, large embryo clutch size, genetic tractability, and suitability for in vivo imaging19,20,21,22,23. Previous protocols have either directly injected LPS into the yolk and hindbrain ventricle of larval zebrafish without mechanistic assessment, or simply added LPS to fish water (culture medium) to induce a lethal systemic immune response24,25,26,27. Herein, we developed a protocol for microinjection of LPS into the brain ventricles, to trigger an innate immune response or neurotoxicity in the 5 days post fertilization (dpf) zebrafish larvae. This response is evidenced by neuronal cell loss, locomotory behavior deficit, increased nitrite oxide release, activation of inflammatory gene expression, and recruitment of neutrophils in the zebrafish brain at 24 h after injection.

Protocol

AB wild-type zebrafish and transgenic zebrafish lines elavl3:mCherry, ETvmat2:GFP, and mpo:EGFP were obtained from the Institute of Chinese Medical Sciences (ICMS). Ethical approval (UMARE-030-2017) for the animal experiments was granted by the Animal Research Ethics Committee, University of Macau, and the protocol follows the institutional animal care guidelines.

1. Zebrafish embryo and larval husbandry

  1. Generate zebrafish embryos (200-300 embryos per mating) by natural pairwise mating as previously reported28.
  2. Prepare egg water (E3) medium stock (60×) by dissolving 34.8 g of NaCl, 1.6 g of KCl, 5.8 g of CaCl2·2H2O, and 9.78 g of MgCl2·6H2O in ddH2O to a final volume of 2 L and adjust pH to 7.2 using NaOH and HCl. To prepare working concentration of E3 medium (1×), dilute the stock 60 times in ddH2O. Store at 28.5 °C when not in use.
  3. Use a plastic transfer pipette to transfer the zebrafish embryos to a dish containing E3 medium. Raise the embryos at 28.5 °C in an incubator and monitor their development and health. Remove dead embryos and replace unclean E3 medium with fresh medium daily.
  4. For zebrafish imaging experiments, use a plastic transfer pipette to collect 0-2 h post fertilization (hpf) embryos (around 200 eggs) in approximately 15 mL of 1× E3 medium containing 0.003% N-phenylthiourea (PTU).
    NOTE: PTU can inhibit the formation of melanophores during embryogenesis29. Treatment of embryos with PTU during embryogenesis can improve signal detection in microscopy or expression of fluorescence30.
  5. Maintain the zebrafish embryos under the above conditions until embryos reach the desired developmental larval stage.

2. Preparing for microinjection

  1. Prepare for the injection by pulling glass capillaries using a micropipette puller (see Table of Materials), following the five step protocol for glass capillary tube pulling (Table 1).
  2. Open the tip of needle (thin wall glass capillaries [3.5 in] with filament, OD 1.14 mm) to the appropriate size at an angle using forceps (Figure 2A).
  3. Fill the needle with 0.1 mL of mineral oil to ensure that there are no bubbles.
  4. Remove the screw cap of the steel needle of the microinjection apparatus. Align the glass needle hole with the steel needle and then tighten the screw cap. Mount the loaded needle microinjection apparatus in a micromanipulator (see Table of Materials).
  5. Adjust the position of the microinjection apparatus so that the micromanipulator can flexibly move the apparatus under the microscope. Discharge a certain volume of paraffin oil to make the steel needle enter the capillary glass tube.
  6. Drop the injection solution (such as 1× PBS or 5 mg/mL LPS) on a glass slide sterilized with 70% ethanol and adjust the microinjection apparatus so that the tip is inserted into the liquid drop. Load ~2 µL of injection solution into the needle.
  7. Set up the micromanipulator (fine adjustment settings of up, down, left, and right) so that the needle tip of the microinjection apparatus is in the same field of vision as the larvae on high magnification (Figure 2B).

3. Mounting zebrafish for microinjections

NOTE: Zebrafish brain development occurs within 3 dpf and matures at 5 dpf with a well-developed central nervous system31,32. Therefore, 5 dpf larvae are already suitable for studying LPS-mediated neuronal damage as well as behavioral and inflammatory responses.

  1. Inject the zebrafish larvae within approximately 30 min of reaching the stage of interest, to maintain the consistency of injection timing.
  2. To anesthetize the zebrafish larvae, combine tricaine with clean fish tank water (final concentration of 0.02% w/v tricaine).
  3. Melt a solution of 2% agarose in ddH2O using a microwave. Pour the molten agarose into a plastic dish. The 2% agarose-coated plastic dish can be stored at 4 °C for up to 2 weeks.
  4. Use a plastic transfer pipette to transport anesthetized larvae to the center of the 2% agarose-coated plastic dish. Orient the mounted larvae with the brain side up for needle access.

4. Injecting the brain ventricle

  1. Adjust the magnification of the microscope so that the brain ventricular structure of zebrafish is clearly displayed in the field of vision (Figure 2B).
  2. Place the needle carefully above the brain tectum (Figure 2C).
  3. Puncture the skin of the zebrafish brain with the needle tip slowly using the micromanipulator.
  4. Press the foot pedal to eject 1 nL of 1x PBS or different concentrations of LPS (1.0, 2.5, and 5.0 mg/mL) (see Table of Materials). Successful ventricle injection images at which brain ventricle was injected with 1 nL of 1% Evans blue dye (diluted in PBS) are shown as an example (Figure 2D). Transfer the larvae to clean E3 medium immediately after the injection. After 24 h, collect the larvae for microscopic imaging, locomotive behavioral assay, and determination of other indicators.

5. Imaging

  1. Prepare 1.5% low-melt agarose solution in E3 medium and heat it in a microwave to form a clear liquid.
  2. Use a clean plastic transfer pipette to transport the larvae to a glass slide and remove as much water as possible.
  3. Use a plastic transfer pipette to add a drop of 1.5% low-melt agarose to the larvae.
    NOTE: Cool the low-melt agarose in the pipette for a while before adding so as not to injure the larvae.
  4. Use a 1 mL syringe needle to orient the larvae. Wait until the agarose cools down and solidifies before starting imaging.
  5. Observe and photograph the neuron region in the whole brain of Tg(ETvmat2:EGFP) and Tg(elavl3:mCherry) zebrafish, as well as the recruitment of neutrophils in the Tg(mpo:EGFP) zebrafish brain under a fluorescence stereo microscope (see Table of Materials).
    NOTE: Fluorescence microscope settings used for imaging are shown below. Tg(ETvmat2:EGFP) zebrafish brain (excitation wavelength: 450-490 nm, emission wavelength: 500-550 nm, visual magnification: 100x); Tg(elavl3:mCherry) zebrafish brain (excitation wavelength: 541-551 nm, emission wavelength: 590 nm, visual magnification: 100x); Tg(mpo:EFGP) zebrafish brain (excitation wavelength: 450-490 nm, emission wavelength: 500-550 nm, visual magnification: 63x).
  6. Measure and analyze the fluorescence intensity and length of the Ra neuron region in Tg(ETvmat2:EGFP) zebrafish and the fluorescence intensity of Tg(elavl3:mCherry) zebrafish brain neurons using ImageJ software. Manually count the neutrophils in the brain region of Tg(mpo:EFGP) zebrafish.

6. Determination of gene expression markers

  1. At 24 h after LPS brain ventricular injection, proceed with the determination of gene expression markers. To do so, anesthetize zebrafish larvae with 0.02% tricaine (as mentioned in step 3.2).
  2. Use two 1 mL syringes to separate the head portions of the larvae (40 larvae per group) without the eye and yolk sac regions (Figure 2E).
  3. Extract RNA from the larval head portions.
    1. For RNA extraction, homogenize the head portion with 200 µL of RNA extraction reagent (see Table of Materials) using a tissue grinder (see Table of Materials) at a rotation speed of 11,000 rpm for 5 s.
    2. Perform RNA extraction using the chloroform-isopropanol method. To do so, add 40 µL chloroform, shake the tubes vigorously, and incubate them at room temperature for 10 min. Centrifuge the samples at 12,000 x g for 15 min at 4 °C.
    3. Transfer the aqueous phase to a fresh tube (about 100 µL) and add 100 µL of isopropanol. Incubate for 10 min and then centrifuge at 12,000 x g for 10 min at 4 °C. Remove the supernatant.
    4. Add 200 µL of 75% ethanol to wash the RNA pellet. Vortex the samples briefly and then centrifuge at 7500 x g for 5 min at 4 °C. Discard the supernatant and wash the RNA pellet again.
    5. Air dry the RNA pellet for 5-10 min, then add 30 µL of RNase-free water to dissolve the RNA pellet. Check the purity (ratio of absorbance at 260 nm and 280 nm) and integrity of RNA using a microvolume spectrophotometer (see Table of Materials).
  4. Synthesize cDNA from the RNA extracted in step 6.3, using reverse transcriptase with random primers (see Table of Materials).
    1. Add 1 µL of random primers, 1 µL of dNTPs, 1 µg of RNA, and distilled water (total volume to 12 µL) to a nuclease-free tube. Heat the mixture to 65 °C for 5 min and quick chill on ice.
    2. Add 1 µL of 0.1 M DTT, 1 µL of RNase inhibitor, 4 µL of 5× first-strand buffer, and 1 µL of M-MLV reverse transcriptase (total volume: 20 µL) to the tube. Mix gently and incubate the tube at 25 °C for 2 min, followed by 42 °C for 50 min. Inactivate the reaction by heating at 70 °C for 15 min.
  5. Perform real time PCR on a qPCR System (see Table of Materials) using a commercially available RT-qPCR kit (see Table of Materials) to determine the expression of the target genes(IL-1β, IL-6, and TNF-α). The reaction mixture (20 µL) contained 10 µL of SYBR green, 0.4 µL of ROX reference dye, 0.8 µL each of the forward and reverse primers, 6 µL of ddH2O, and 2 µL of template cDNA (1 µg). Perform PCR amplification under the conditions: 95 °C for 30 s, followed by 40 cycles of 95 °C for 5 s and 60 °C for 34 s, and with a dissociation stage of 95 °C for 15 s, 60 °C for 60 s, and 95 °C for 15 s.
  6. Normalize the mRNA levels of the target genes to that of a housekeeping gene, elongation factor 1 α (Ef1α). Calculate the expression levels for each target gene by the 2−ΔΔCT method33. The primer sequences of each gene are described in Table 2.
  7. For the determination of nitric oxide, homogenize the head portion (obtained in step 6.2) in 100 µL of cold PBS using a tissue grinder. Centrifuge the resultant PBS and head portion suspension at 12,000 x g for 15 min at 4 °C. Collect the lysates and perform nitrite concentration assay34 using a commercially available kit (see Table of Materials).

7. Zebrafish locomotive behavioral assay

  1. At 24 h after LPS brain ventricular injection, transfer the zebrafish larvae to the wells of a 96-well square microplate individually. Add 300 µL of E3 medium to each well and then incubate the larvae for 4 h to acclimate to the testing plate.
  2. Transfer the larvae-loaded microplate to the zebrafish tracking box (see Table of Materials). Turn on the light source and then incubate the larvae in the testing box for 30 min to acclimate the environment.
  3. Monitor and record the zebrafish behavior using an automated video tracking system. Record 12 sessions (5 min each, total 1 h) for each zebrafish. Define the total distance (consists of inactive, small, and large distances) as the distance (in mm) that each fish moved during a 60 min tracking period.

8. Statistical analysis

  1. Perform statistical analyses using standard analysis software (see Table of Materials).
  2. Perform statistical analysis of differences between two groups using ordinary one-way ANOVA. Calculate Pearson's correlation coefficient to assess the strength of correlations. P < 0.05 was considered significant in all analyses.

Representative Results

The workflow described here presents a new, quick, and efficient methodology for inducing LPS-mediated neuroinflammation and neurotoxicity in zebrafish larvae. In this described protocol, 5 dpf zebrafish were injected with LPS (Figure 1) into brain ventricles using a microinjector (Figure 2AC). Successful injection into the brain ventricle site was verified using 1% Evans blue stain (Figure 2D). The zebrafish head was separated from its eyes and body using syringes (Figure 2E) to exclude any influence of inflammatory cytokine expression and nitric oxide release in the zebrafish body on the determination of neuroinflammation and neurotoxicity in the brain.

The same volume of PBS (as LPS) was injected into the zebrafish brain ventricular area as a sham-operated control. No significant differences were observed between the control and sham-operated groups in the neurons in particular from especially the anterior group of raphe nuclei (Ra) (Figure 3AC), fluorescence integrated density of the brain neurons (Figure 3D,E), the total distance of movement of the zebrafish (Figure 4A,B), NO production and mRNA expression of pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) (Figure 4AD), and recruitment of neutrophils into the larval zebrafish brain (Figure 6A,B). These results demonstrated that proper microinjection does not cause any neurotoxicity and neuroinflammation in zebrafish.

After treatment for 24 h, brain ventricular injection of LPS induced neurotoxicity in zebrafish. LPS (1-5 mg/mL) induced a significant loss of Ra neurons in the brain of Tg(ETvmat2:GFP) larval zebrafish compared to the control and sham groups (Figure 3AC). The transgenic line elav13:mCherry zebrafish outlines the neuronal cells with the nuclear red fluorescent protein35. As shown in Figure 3D,E, 2.55 mg/mL LPS led to significant changes in the fluorescence integrated density of the brain neurons in this larval zebrafish line. However, the 1 mg/mL LPS injection group showed no effect on the fluorescence integrated density of the brain neurons in comparison with the control and sham groups. Further, 5 mg/mL LPS induced a locomotion deficiency (Figure 4A) and decreased the total distance of movement of zebrafish over a 60 min tracking period (Figure 4B). The results demonstrated that 1-2.5 mg/mL LPS could induce loss of neurons but no significant locomotion deficiency.

In addition, brain ventricular injection of LPS can also activate the inflammatory response in the zebrafish brain. NO production (Figure 5A) and mRNA expression of pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) (Figure 5BD) in the head of zebrafish larvae were increased on 2.5-5 mg/mL LPS treatment compared to the expression in the control and sham groups. After 1-5 mg/mL LPS injection, the recruitment of neutrophils into the larval zebrafish brain was observed (Figure 6A), resulting in a significant increase in the number of neutrophils in the Tg(mpo:EGFP) zebrafish brain region (Figure 6B).

Step Operating time (sec) Heat level Action
T1 L> H80-89 P1L005
T2 1.6-3 H00
T3 L> H00 P2L001c
T4 3 H00 COOL
T5 0 H00

Table 1: Five-step protocol for glass capillary tube pulling.

Primer name Sequence
IL-1β forward  5’-CATTTGCAGGCCGTCACA-3’
IL-1β reverse 5’-GGACATGCTGAAGCGCACTT-3’
IL-6 forward  5’-TCAACTTCTCCAGCGTGATG-3’
IL-6 reverse  5’-TCTTTCCCTCTTTTCCTCCTG-3’
TNF-α forward  5’-GCTGGATCTTCAAAGTCGGGTGTA-3’
TNF-α reverse  5’-TGTGAGTCTCAGCACACTTCCATC-3’
Ef1α forward  5’-GCTCAAACATGGGCTGGTTC-3’
Ef1α reverse 5’-AGGGCATCAAGAAGAGTAGTACCG-3’

Table 2: Primers used in real time qPCR.

Figure 1
Figure 1: General structure of lipopolysaccharide (LPS). Please click here to view a larger version of this figure.

Figure 2
Figure 2: Microinjection setup, body posture and position of zebrafish, and separation of head portion. (A) Glass needle selection: use a tweezer to cut the tip of a pre-pulled needle under the microscope, to obtain a needle with a similar opening as shown in the figure. (B) Adjust the focal length of the microscope so that the brain ventricular area of zebrafish larvae can be observed at high magnification (outlined in black). Light blue circles indicate the injection site. (C) The mounted larvae need to be oriented with the brain side up for needle access (brain tectum indicated by red circle). (D) Demonstration of successful ventricular injection with Evans blue in zebrafish larvae brain. (E) Zebrafish head portion without the eye and yolk sac regions. Please click here to view a larger version of this figure.

Figure 3
Figure 3: Brain ventricular injection of LPS ablates neurons after 24 h in zebrafish larvae. (A) (Top) Representative fluorescence microscopy images of vmat2:GFP zebrafish after treatment with different concentrations of LPS (red brackets indicate raphe nuclei [Ra] neurons; scale bar = 265.2 µm). (Bottom) Ra neuronal region was enlarged to improve the morphologic visualization. (B,C) Mean fluorescence intensity and length of the Ra neuron region in vmat2:GFP zebrafish larvae. (D,E) Representative morphology (scale bar = 265.2 µm) and mean fluorescence intensity of Tg(elavl3:mCherry) zebrafish brain neurons. Data are expressed as a percentage of the control group. *P < 0.05 and **P < 0.01 versus control group. Please click here to view a larger version of this figure.

Figure 4
Figure 4: Brain ventricular injection of LPS induces locomotion deficiency after 24 h in zebrafish larvae. (A) Representative patterns of zebrafish locomotion traces. In the digital tracking map, high-speed movement is represented by red lines (> 6.6 mm/s); medium-speed movement is depicted by green lines (3.3−6.6 mm/s); low-speed movement is depicted by black lines (< 3.3 mm/s). (B) Quantitative analysis of the average total distance traveled by the zebrafish in 60 min. *P < 0.05 versus control group. Please click here to view a larger version of this figure.

Figure 5
Figure 5: Brain ventricular injection of LPS increases pro-inflammatory mediators. (A) Nitric oxide levels were measured using Griess reagent. (BD) The gene expression levels of interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) in the zebrafish head were investigated by qPCR. *P < 0.05 and **P < 0.01 versus control group. Please click here to view a larger version of this figure.

Figure 6
Figure 6: LPS brain ventricular microinjection leads to the recruitment of neutrophils in the zebrafish brain after 24 h. (A) Migration of neutrophils (area inside the red circle) into the head of larvae after LPS brain ventricular injection (scale bar = 851.1 µm). (B) The number of neutrophils in larvae heads after LPS brain ventricular injection. *P < 0.05 and **P < 0.01 versus control group. Please click here to view a larger version of this figure.

Supplementary File 1: Raw data Please click here to download this File.

Discussion

An increasing amount of epidemiological and experimental data implicate chronic bacterial and viral infections as possible risk factors for neurodegenerative diseases36. The infection triggers the activation of inflammatory processes and host immune responses37. Even if the response acts as a defense mechanism, overactivated inflammation is detrimental to neurogenesis, and the inflammatory environment does not allow for the survival of newborn neurons38. As a result, it causes damage to host neuronal functions and viability. Studies indicate that inflammation plays a significant role in the pathophysiology of neurodegeneration39.

As a frequently studied pathogenic endotoxin, LPS has been implicated in the inhibition of neurogenesis and neurodegeneration. LPS activation of inflammatory processes significantly impairs neurogenesis, partially through the production of NO, TNF-α, IL-6, and IL-1β40. A growing body of evidence demonstrates that LPS causes behavior deficits and neuronal loss, and influences neurogenesis progression when centrally injected in neurodegenerative rodent models10,38. Zebrafish models have been widely used as alternative experimental models to study immune responses41 and screen new anti-inflammatory drugs. The innate and adaptive immune systems of zebrafish are similar to those of mammals42. Furthermore, some studies have identified several inflammatory cytokines and receptors present in mammals in the zebrafish CNS43. Earlier studies suggest that immersing zebrafish embryos/larvae in LPS or injecting LPS into the yolk of zebrafish larvae can induce the immune response and increase pro-inflammatory factors associated with inflammation44,45. However, the specific effect of LPS on zebrafish nervous tissue, and on the induction of neuroinflammation, is not yet known.

Although rodent models have many advantages over other animal models, their limitations in terms of real-time in vivo imaging and drug screening are obvious. In vivo imaging is widely used to investigate the mechanisms underlying nervous system development and pathological brain changes as a powerful and noninvasive tool46,47. Due to the optical transparency of zebrafish embryos and larvae, they are well suited to live imaging experiments of brain observation48,49. In particular, the small size of zebrafish, and their ability to produce thousands of embryos, mean that high-throughput drug screening can be undertaken using zebrafish embryos or larvae50,51. Moreover, with developments in science and technology, robotic microinjections can be delivered precisely and effectively, and can be used to inject large quantities of embryos or larvae52,53. The application of the microrobotic injection system to neuronal research, for timely injection of materials into large numbers of embryos or larvae, will facilitate large-scale screening of biomolecules and drug compounds.

In this study, zebrafish at 5 dpf were injected with LPS at a concentration of 2.5-5 mg/mL; this was determined as the optimum condition for neuroinflammation model development. To our knowledge, this methodology has not been described in the literature. Consequently, brain ventricular microinjection of LPS in zebrafish larvae was able to cause loss of neurons and locomotion deficiency. Moreover, our results demonstrated that LPS-induced neuroinflammation increases the levels of proinflammatory mediators such as NO, TNF-α, IL-6, and IL-1β, and leads to the recruitment of neutrophils in the larval zebrafish brain at 24 h after injection. In other animal models, LPS injection can also promote the development of inflammation and cause neuropathological alterations in the brain13,54. The results from this study further our understanding of neuroinflammatory pathways. In this method, it should be noted that the opening of needles for microinjection should not be too large to avoid brain damage caused by mechanical operation, and a reasonable amount of force should be applied to avoid damaging the larvae. In addition, it is important to separate the head from the eyes and body of zebrafish for the determination of inflammatory factors and nitric oxide, as this will help obtain directional results specifically reflecting the neuroinflammation induced by LPS brain ventricular injection.

A slight disadvantage of this method is that, due to the small size of zebrafish larvae, the amounts of biomolecules such as total mRNA obtained by homogenization and extraction is lower than that of the mouse model. However, zebrafish is able to spawn frequently with several hundred of eggs every week. Increasing the number of zebrafish larvae used in each group can provide sufficient amounts of extracted biomolecules for different biochemical assays. In conclusion, this method induces neurotoxicity and an immune response in the larval zebrafish brain. Due to the transparency of zebrafish, changes in the larval live zebrafish brain can be better understood via in vivo imaging. The technique described here is an excellent tool for quickly and efficiently evaluating possible anti-neuroinflammatory drugs.

Divulgations

The authors have nothing to disclose.

Acknowledgements

This study was supported by grants from the Science and Technology Development Fund (FDCT) of Macao SAR (Ref. No. FDCT0058/2019/A1 and 0016/2019/AKP), Research Committee, University of Macau (MYRG2020-00183-ICMS and CPG2022-00023-ICMS), and National Natural Science Foundation of China (No. 81803398).

Materials

Agarose Sigma-Aldrich A6361
Agarose, low gelling temperature Sigma-Aldrich A9414
Drummond Nanoject III Programmable Nanoliter Injector Drummond Scientific 3-000-207
Fluorescence stereo microscopes Leica M205 FA
GraphPad Prism software GraphPad Software Ver. 7.04
Lipopolysaccharides from Escherichia coli O111:B4 Sigma-Aldrich L3024
Manual micromanipulator World Precision Instruments M3301
Mineral oil Sigma-Aldrich M5904
Mx3005P qPCR system Agilent Technologies Mx3005P
Nanovue plus spectrophotometer Biochrom 80-2140-46
Nitrite concentration assay kit Beyotime Biotechnology S0021M
Phosphate-buffered saline Sigma-Aldrich P4417
Programmable Horizontal Pipette Puller World Precision Instruments PMP-102
PTU (N-Phenylthiourea) Sigma-Aldrich P7629
Random primers Takara 3802
SuperScript II Reverse Transcriptase Invitrogen 18064014
SYBR Premix Ex Taq II kit Accurate Biology AG11701
The 3rd Gen Tgrinder Tiangen OSE-Y30
Thin wall glass capillaries (4”) with filament, OD 1.5 mm World Precision Instruments TW150F-4
Tricaine (3-amino benzoic acid ethyl ester) Sigma-Aldrich A-5040
TRNzol Universal reagent Tiangen DP424
Zebrafish tracking box ViewPoint Behavior Technology

References

  1. Xanthos, D. N., Sandkuhler, J. Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nature Reviews Neuroscience. 15 (1), 43-53 (2014).
  2. Fan, L. W., Pang, Y. Dysregulation of neurogenesis by neuroinflammation: key differences in neurodevelopmental and neurological disorders. Neural Regeneration Research. 12 (3), 366-371 (2017).
  3. Kwon, H. S., Koh, S. H. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Translational Neurodegeneration. 9 (1), 42 (2020).
  4. Block, M. L., Zecca, L., Hong, J. S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience. 8 (1), 57-69 (2007).
  5. Tan, E. K., et al. Parkinson disease and the immune system-associations, mechanisms and therapeutics. Nature Reviews Neurology. 16 (6), 303-318 (2020).
  6. Borsini, A., Zunszain, P. A., Thuret, S., Pariante, C. M. The role of inflammatory cytokines as key modulators of neurogenesis. Trends in Neurosciences. 38 (3), 145-157 (2015).
  7. Kouhsar, S. S., Karami, M., Tafreshi, A. P., Roghani, M., Nadoushan, M. R. Microinjection of l-arginine into corpus callosum cause reduction in myelin concentration and neuroinflammation. Brain Research. 1392, 93-100 (2011).
  8. Couch, Y., Davis, A. E., Sá-Pereira, I., Campbell, S. J., Anthony, D. C. Viral pre-challenge increases central nervous system inflammation after intracranial interleukin-1β injection. Journal of Neuroinflammation. 11, 178 (2014).
  9. Zhao, J., et al. Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice. Scientific Reports. 9 (1), 5790 (2019).
  10. Deng, I., Corrigan, F., Zhai, G., Zhou, X. F., Bobrovskaya, L. Lipopolysaccharide animal models of Parkinson’s disease: Recent progress and relevance to clinical disease. Brain Behavior and Immunity-Health. 4, 100060 (2020).
  11. Hernandez Baltazar, D., et al. Does lipopolysaccharide-based neuroinflammation induce microglia polarization. Folia Neuropathologica. 58 (2), 113-122 (2020).
  12. Dutta, G., Zhang, P., Liu, B. The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery. Fundamental and Clinical Pharmacology. 22 (5), 453-464 (2008).
  13. Castaño, A., Herrera, A. J., Cano, J., Machado, A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. Journal of Neurochemistry. 70 (4), 1584-1592 (1998).
  14. Perez-Dominguez, M., Avila-Munoz, E., Dominguez-Rivas, E., Zepeda, A. The detrimental effects of lipopolysaccharide-induced neuroinflammation on adult hippocampal neurogenesis depend on the duration of the pro-inflammatory response. Neural Regeneration Research. 14 (5), 817-825 (2019).
  15. Liu, M., Bing, G. Lipopolysaccharide animal models for Parkinson’s disease. Parkinson’s Disease. 2011, 327089 (2011).
  16. Wilt, B. A., et al. Advances in light microscopy for neuroscience. Annual Review of Neuroscience. 32, 435-506 (2009).
  17. Huang, S. H., et al. Optical volumetric brain imaging: speed, depth, and resolution enhancement. Journal of Physics D: Applied Physics. 54 (32), 323002 (2021).
  18. Ahn, C., et al. Overcoming the penetration depth limit in optical microscopy: Adaptive optics and wavefront shaping. Journal of Innovative Optical Health Sciences. 12 (04), 1930002 (2019).
  19. Saleem, S., Kannan, R. R. Zebrafish: an emerging real-time model system to study Alzheimer’s disease and neurospecific drug discovery. Cell Death Discovery. 4, 45 (2018).
  20. Hung, M. W., et al. From omics to drug metabolism and high content screen of natural product in zebrafish: a new model for discovery of neuroactive compound. Evidence-Based Complementary and Alternative. 2012, 605303 (2012).
  21. Fontana, B. D., Mezzomo, N. J., Kalueff, A. V., Rosemberg, D. B. The developing utility of zebrafish models of neurological and neuropsychiatric disorders: A critical review. Experimental Neurology. 299, 157-171 (2018).
  22. Sonawane, P. M., et al. A water-soluble boronate masked benzoindocyanin fluorescent probe for the detection of endogenous mitochondrial peroxynitrite in live cells and zebrafish as inflammation models. Dyes and Pigments. 191, 109371 (2021).
  23. Sonawane, P. M., et al. Phosphinate-benzoindocyanin fluorescent probe for endogenous mitochondrial peroxynitrite detection in living cells and gallbladder access in inflammatory zebrafish animal models. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 267, 120568 (2022).
  24. Yang, L. L., et al. Endotoxin molecule lipopolysaccharide-induced zebrafish inflammation model: a novel screening method for anti-inflammatory drugs. Molecules. 19 (2), 2390-2409 (2014).
  25. Rojas, A. M., Shiau, C. E. Brain-localized and intravenous microinjections in the larval zebrafish to assess innate immune response. Bio-Protocol. 11 (7), 3978 (2021).
  26. Brugman, S. The zebrafish as a model to study intestinal inflammation. Developmental and Comparative Immunology. 64, 82-92 (2016).
  27. Kim, E. A., et al. Anti-inflammatory effect of Apo-9′-fucoxanthinone via inhibition of MAPKs and NF-kB signaling pathway in LPS-stimulated RAW 264.7 macrophages and zebrafish model. International Immunopharmacology. 59, 339-346 (2018).
  28. He, Y. L., et al. Angiogenic effect of motherwort (Leonurus japonicus) alkaloids and toxicity of motherwort essential oil on zebrafish embryos. Fitoterapia. 128, 36-42 (2018).
  29. Lister, J. A. Development of pigment cells in the zebrafish embryo. Microscopy Research and Technique. 58 (6), 435-441 (2002).
  30. Karlsson, J., von Hofsten, J., Olsson, P. E. Generating transparent zebrafish: a refined method to improve detection of gene expression during embryonic development. Marine Biotechnology. 3 (6), 522-527 (2001).
  31. d’Amora, M., Giordani, S. The utility of zebrafish as a model for screening developmental neurotoxicity. Frontiers in Neuroscience. 12, 976 (2018).
  32. Kalueff, A. V., Stewart, A. M., Gerlai, R. Zebrafish as an emerging model for studying complex brain disorders. Trends in Pharmacological Sciences. 35 (2), 63-75 (2014).
  33. Livak, K. J., Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25 (4), 402-408 (2001).
  34. Zhang, B., et al. Effects of a dammarane-type saponin, ginsenoside Rd, in nicotine-induced vascular endothelial injury. Phytomedicine. 79, 153325 (2020).
  35. Chen, Y., Li, G., Law, H. C. H., Chen, H., Lee, S. M. Determination of oxyphylla A enantiomers in the fruits of Alpinia oxyphylla by a chiral high-performance liquid chromatography-multiple reaction monitoring-mass spectrometry method and comparison of their in vivo biological activities. Journal of Agricultural and Food Chemistry. 68 (40), 11170-11181 (2020).
  36. De Chiara, G., et al. Infectious agents and neurodegeneration. Molecular Neurobiology. 46 (3), 614-638 (2012).
  37. Sochocka, M., Diniz, B. S., Leszek, J. Inflammatory response in the CNS: friend or foe. Molecular Neurobiology. 54 (10), 8071-8089 (2017).
  38. Whitney, N. P., Eidem, T. M., Peng, H., Huang, Y., Zheng, J. C. Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disorders. Journal of Neurochemistry. 108 (6), 1343-1359 (2009).
  39. Terzi, M., et al. The use of non-steroidal anti-inflammatory drugs in neurological diseases. Journal of Chemical Neuroanatomy. 87, 12-24 (2018).
  40. Shohayeb, B., Diab, M., Ahmed, M., Ng, D. C. H. Factors that influence adult neurogenesis as potential therapy. Translational Neurodegeneration. 7, 4 (2018).
  41. Sullivan, C., Kim, C. H. Zebrafish as a model for infectious disease and immune function. Fish and Shellfish Immunology. 25 (4), 341-350 (2008).
  42. Meeker, N. D., Trede, N. S. Immunology and zebrafish: spawning new models of human disease. Developmental and Comparative Immunology. 32 (7), 745-757 (2008).
  43. Morales Fenero, C. I., Colombo Flores, A. A., Camara, N. O. Inflammatory diseases modelling in zebrafish. World Journal of Experimental Medicine. 6 (1), 9-20 (2016).
  44. Mottaz, H., et al. Dose-dependent effects of morphine on lipopolysaccharide (LPS)-induced inflammation, and involvement of multixenobiotic resistance (MXR) transporters in LPS efflux in teleost fish. Environmental Pollution. 221, 105-115 (2017).
  45. Novoa, B., Bowman, T. V., Zon, L., Figueras, A. LPS response and tolerance in the zebrafish (Danio rerio). Fish and Shellfish Immunology. 26 (2), 326-331 (2009).
  46. Garcia-Alloza, M., Bacskai, B. J. Techniques for brain imaging in vivo. Neuromolecular Medicine. 6 (1), 65-78 (2004).
  47. Ford, J., et al. At a glance: An update on neuroimaging and retinal imaging in Alzheimer’s disease and related research. Journal of Prevention of Alzheimer’s Disease. 9 (1), 67-76 (2022).
  48. Bercier, V., Rosello, M., Del Bene, F., Revenu, C. Zebrafish as a model for the study of live in vivo processive transport in neurons. Frontiers in Cell and Developmental Biology. 7, 17 (2019).
  49. Antinucci, P., Hindges, R. A crystal-clear zebrafish for in vivo imaging. Scientific Reports. 6, 29490 (2016).
  50. Poureetezadi, S. J., Donahue, E. K., Wingert, R. A. A manual small molecule screen approaching high-throughput using zebrafish embryos. Journal of Visualized Experiments. (93), e52063 (2014).
  51. Zon, L. I., Peterson, R. T. In vivo drug discovery in the zebrafish. Nature Reviews Drug Discovery. 4 (1), 35-44 (2005).
  52. Chi, Z., Xu, Q., Zhu, L. A review of recent advances in robotic cell microinjection. Ieee Access. 8, 8520-8532 (2020).
  53. Wang, W., Liu, X., Gelinas, D., Ciruna, B., Sun, Y. A fully automated robotic system for microinjection of zebrafish embryos. PLoS One. 2 (9), 862 (2007).
  54. Fu, H. Q., et al. Prolonged neuroinflammation after lipopolysaccharide exposure in aged rats. PLoS One. 9 (8), 106331 (2014).

Play Video

Citer Cet Article
He, Y., Lee, S. M. Y. Brain Ventricular Microinjections of Lipopolysaccharide into Larval Zebrafish to Assess Neuroinflammation and Neurotoxicity. J. Vis. Exp. (186), e64313, doi:10.3791/64313 (2022).

View Video